Skip to main content
. 2020 Oct 12;33(6):603–614. doi: 10.20524/aog.2020.0550

Figure 2.

Figure 2

Drug therapy effects on pathways linking NAFLD and atrial fibrillation

MMP, matrix metalloproteinase; TGF-β, transforming growth factor-β; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon-like peptide-1; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker